Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosnilimab in Moderate to Severe Ulcerative Colitis
2023-508679-34-00Phase 2Completed
- Sponsor
- AnaptysBio, Inc.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Rosnilimab with Placebo (2 arms). Primary endpoint: Mean change from baseline in modified Mayo Score (mMS) at Week 12. Started Mar 2024; status: completed.
02
Drugs
rosnilimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-508679-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508679-34-00.